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ABSTRACT
Objective: Urinary tract infections are considered among the most common infections, occurring either in the community or health-care setting. We 
are left with very few options for the treatment due to rapid development of antibiotic resistance among the organisms. To find out the prevalence of 
various types of β-lactamases among urinary isolates.
Methods: Seven antibiotic discs (HiMedia) were placed in combinations and approximation in a particular sequence on a 90 mm diameter Mueller-
Hinton agar plate.
Results: Out of a total 165 urinary isolates, 66 (40%) isolates were positive for extended spectrum β-lactamase (ESBL) production, AmpC β-lactamases 
(AmpC) activity was present in 31 (18.78%) isolates, co-production of both ESBL and AmpC was seen in 16 (9.69%) isolates, 3 (1.81%) isolates 
produced metallo β-lactamase (MBL), 2 (1.21%) isolates produced both MBL, and ESBL and 1 (0.60%) isolates were positive for inducible third 
generation cephalosporin resistance.
Conclusion: With the presence of such high prevalence of various β-lactamases in clinical isolates of gram-negative bacilli and also other types of 
antibiotic resistance, antibiotic policy should be made, and strict adherence should be followed.
Keywords: Extended spectrum β-lactamase, AmpC β-lactamase, Metallo β-lactamase.
INTRODUCTION
Urinary tract infections (UTIs) are considered among the most common 
infectious diseases occurring in either the community or health-care 
setting [1].
Hence, these infections should be treated with appropriate antibiotics 
to avoid the development of the resistance among the organisms. We 
are very close to the era when no antibiotic will be effective for treating 
bacterial infections. Antibiotic resistance is increasing at an alarming 
speed and is really a matter of serious concern. Inappropriate use of 
antibiotics in medical and veterinary practice is responsible for the 
current situation.
Beta-lactam group of antibiotics is commonly used drugs for treating 
various types of infections including UTIs.
Unfortunately, Gram-negative bacteria have acquired resistance to beta-
lactam group of antibiotics and other commonly used antibiotics. Hence, 
we are left with very limited options. Extended spectrum β-lactamases 
(ESBLs) were first reported in Europe in 1983 [2]. Plasmid-mediated 
AmpC β-lactamases (AmpC) was reported for the first time in 1988 [3].
There are many types of bacterial resistance in Gram-negative bacteria, 
e.g., resistance due to ESBL production [4], AmpCβ production [5], 
due to porin deficiency [6], and efflux mechanism [7]. Among these, 
extended spectrum β-lactamase and AmpC β-lactamase found to be the 
most common [8].
METHODS
The study was conducted in 2016 between March and July on isolates 
from patients with significant bacteriuria from both in patient 
department and outpatient department. These clinical isolates were 
nonrepetitive.
Two 90 mm plates of Mueller-Hinton agar were used. One (Plate 1) for 
detecting various types of enzymes and the second plate (Plate 2) for 
susceptibility to various antibiotics depending on the type of organism 
isolated, lower UTI or complicated UTI, age, pregnancy, and renal 
function or any other clinical condition of the patient.
Plate 1: It was inoculated with 0.5 McFarland standard of the organism to 
be tested and incubated at 35±2°C in ambient air. Seven antibiotic discs 
were placed in a specific order for the expression of various enzymes, 
e.g., ESBLs, AmpC, inducible AmpC, and MBL (metallo β-lactamases) 
as shown in Fig. 1. Ceftazidime (CAZ) 30 mg, cefoxitin (CX) 30 mg, 
imipenem (IPM) 10 mg, IPM + EDTA (IE) 10+30 mg, and cefepime 
(CPM) 30 mg.
CPM + clavulanic acid (CFC) 30/10 mg, CX + cloxacillin (CXX) 30/10 mg.
Antibiotic susceptibility was done according to Clinical Laboratory 
Standards Institute (CLSI) guidelines 2016 [9].
All the discs were obtained from HiMedia. Quality control strains 
American Type Culture Collection (ATCC) Escherichia coli 25922 and 
ATCC Klebsiella pneumoniae 700603 were used as ESBL negative and 
positive control, respectively, and were obtained from HiMedia.
ESBL
Combination disc method was used. A difference of increase in diameter 
of ≥ 5 mm in the zone diameter of the CPM alone and combination with 
CFC (CPM + CA) (Fig. 2), was considered as positive for the production 
of ESBL enzyme [10].
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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AmpC
a. When there is difference in the zone of inhibition between CX + 
CXX disc combination and CX alone of ≥4 mm (Fig. 2), indicates the 
production of AmpC [11].
b. AmpC (Inducible): Blunting of the zone of CAZ (reporter substrate) 
toward inducing substrate like CX and IPM by 2 mm (Fig. 6). 
The edge-to-edge distance between CX and CAZ disc should be 
15 mm [12].
Metallo β-lactamases (MBL)
Organisms were suspected to be MBL producer when they were found 
to be resistant to both IPM and meropenem.
MBL production was further confirmed by IE double disk synergy 
test.
An isolate was considered MBL producer when the zone of inhibition 
was ≥5 mm with IE disc as compared to the zone of inhibition produced 
by IPM disc alone [13].
RESULTS
Out of a total 165 isolates, 66 (40%) were positive for ESBL production 
(Fig. 2), 31 (18.78%) were found to produce AmpC (Fig. 3), 16 (9.69%) 
showed co-production of ESBL, and AmpC enzymes (Fig. 4). 3 (1.81%) 
isolates were found positive for MBL production and 2 (1.21%) were 
found to co-produce ESBL and MBL (Fig. 5). Furthermore, 1 (0.60%) 
strain of Citrobacter sp. was found positive for inducible third 
generation cephalosporin resistance (Figs. 6 and 7, Table 1).
DISCUSSION
In this study, we detected β-lactamase enzymes using certain 
combinations and approximation of antibiotic discs in a particular order 
Fig. 1: Plate 1: Placement of discs on Mueller-Hinton agar in a 
specific order
Fig. 2: Plate 2: Extended spectrum β-lactamase
Fig. 3: AmpC β-lactamases
Fig. 4: Extended spectrum β-lactamase and AmpC β-lactamases
Fig. 5: Extended spectrum β-lactamase and Metallo β-lactamase
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It is very important to look for the occurrence of various β-lactamases 
in the isolates to avoid the treatment failure, which may lead to serious 
complications, especially in complicated UTI.
We preferred using CPM (Zwiteronic, also referred to as fourth 
generation cephalosporin) as ESBL screening agent. High-level AmpC 
expression has minimal effect on the activity of CPM, which is the 
reason this drug is considered more reliable for the detection of ESBL 
in the presence of an AmpC [14].
Sensitivity with CX-CXX combination has been found to be (95%) 
and specificity (95%) with cut-off an increase in zone diameter 
of ≥4 mm [11].
Recently, some studies have been carried out looking for the occurrence 
of various enzymes in the clinical isolates of Gram-negative bacteria 
(Table 2). In studies carried out by Oberoi et al. and Kolhapure 
et al. [16,18] they have looked for the co-production of various types 
of enzymes. Fortunately, our study shows the lowest prevalence of MBL 
and MBL + ESBL production.
A previous study conducted by us last year showed good susceptibility 
results for treating some of the uropathogens with nitrofurantoin 
(90.66%) [19]. However, this drug is effective only for treating lower 
UTI because due to rapid elimination, sufficient urinary concentration 
for treating upper UTI is not achieved.
ESBL producing organisms can be treated with β-lactam group of 
drug along with β-lactamase inhibitor combination. Furthermore, 
quinolones and aminoglycosides can be tested for susceptibility. 
If the organism is co-producing AmpC, inhibitors are not effective. 
Although AmpC producing isolates are susceptible to four generation 
cephalosporin, while ESBL producing organisms are variably resistant 
to four generation cephalosporin [20], CPM may not be effective for 
treating ESBL, and AmpC producing bacterial infections due to high 
inoculum effect [21]. The available clinical data have shown that 
carbapenems are more effective than CPM in treating serious infections 
due to large numbers of AmpC producing bacteria [22].
Enterobacter cloacae, Enterobcater aerogenes, Citrobacter freundii, 
and Serratia marcescens, Providencia sp., Morganella morganii, and 
Pseudomonas aeruginosa may develop resistance during prolonged 
therapy with third generation cephalosporin (oxyimino-cephalosporin) 
as a result of derepression of AmpC-lactamase. Therefore, isolates that 
are found initially susceptible may become resistant within 3-4 days 
to determine various β-lactamases singly or in various combination if 
the organism is also producing another enzyme.
Table 1: Prevalence of ESBL, AmpC, MBL, inducible resistance and co-existence of these enzymes among Gram-negative bacilli in urinary isolates
Organisms Total isolates n (%) IR
ESBL AmpC EA MBL ME MA
E. coli 140 53 (37.857) 28 (20) 14 (10) 1 (0.714) 0 0 0
K. pneumoniae 15 9 (60) 2 (13.33) 1 (6.66) 1 (6.66) 1 (6.66) 0 0
Citrobacter spp. 6 2 (33.33) 1 (16.66) 1 (16.66) 1 (16.66) 0 0 1 (16.66)
Proteus mirabilis 2 2 (100) 0 0 0 0 0 0
P. aeruginosa 2 0 0 0 0 1 (50) 0 0
165 66 (40) 31 (18.78) 16 (9.69) 3 (1.81) 2 (1.21) 1 (0.60)
E. coli: Escherichia coli, K. pneumonia: Klebsiella pneumonia, P. mirabilis: Proteus mirabilis, P. aeruginosa: Pseudomonas aeruginosa, ESBL: Extended spectrum β-lactamase, 
AmpC: AmpC β-lactamases, EA: ESBL+AmpC, MBL: Metallo β β-lactamase, ME: MBL+ESBL, MA: MBL+AmpC
Table 2: Recent studies showing prevalence of various β-lactamases in different states of India
Author’s name Year and place ESBL% AmpC% EA% MBL% ME% MA%
Nagedo et al. [15] 2012, Bhopal 70.38 52.05 - 23.05 - -
Oberoi et al. [16] 2013, Amritsar 35.16 5.49 6.59 10.98 8.79 3.67
Haider et al. [17] 2014, Aligarh 54.9 36.6 - 17.9 - -
Kolhapure et al. [18] 2015, Hyderabad 38.52 10.33 9.77 9.20 4.81 6.23
Thakur et al. (our) 2016 Muzaffarnagar 40 18.78 9.69 1.81 1.21 0
ESBL: Extended spectrum β-lactamase, AmpC: AmpC β-lactamases, MBL: Metallo β-lactamase, ME: MBL+ESBL, MA: MBL+AmpC
Fig. 6: Inducible resistance (Blunting of zone of inhibition around 
ceftazidime toward cefoxitin disc)
Fig. 7: Percentage of production of various beta-lactamase 
enzymes extended spectrum β-lactamases, AmpC β-lactamases, 
Metallo β-lactamase, ESBL + AmpC, MBL + ESBL, MBL + AmpC, 
inducible third generation cephalosporin resistance
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after beginning of therapy. Testing of repeat isolates may be warranted. 
CLSI guidelines 2016 [9].
CONCLUSION
With such high prevalence of various β-lactamases in clinical isolates 
of Gram-negative bacilli and also other types of antibiotic resistance, 
antibiotic policy should be made, and strict adherence should be 
followed. Staff members involved in antibiotic susceptibility reporting 
should keep themselves updated with the current knowledge. 
Restricted use of third and fourth generation cephalosporin. Infection 
control practice such as proper hand washing, isolation of the patient 
harboring resistant organism, dealing with outbreaks, and antibiotic 
policy with the appropriate use of antibiotics should be framed.
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